focus -WSS

focus

author：hotspot 2025-09-29 01:06:24 - browse：52

Light hits on the portrait of George Washington on a one dollar bill. The portrait is surrounded by white and red tablets coming out of a pill bottle, as well as some coins — coverage from STAT — Adobe

WASHINGTON — Pharmaceutical companies are doing anything they can to stop President Biden’s Medicare program from being able to negotiate prices for their products, including suing the government. Experts say their efforts might actually benefit Biden by reminding voters that he’s taking on big drug companies.

When Democrats passed a law directing Medicare to negotiate drug prices, it was considered a major achievement. The new law, two decades in the making, gives Biden an accomplishment to both tout for himself and criticize Republicans for opposing — no Republicans voted to let Medicare negotiate drug prices.

Medicare price negotiation is popular with voters, as are the law’s price-inflation limits, and it includes additional, direct benefits for older adults that are easy to understand. It caps annual out-of-pocket retail-drug spending for seniors and people with disabilities, and it caps their monthly spending on insulin at $35.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： 6 phony surgeries that take placebo to the extreme

leisure time

WSS

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Senators push IRS to launch nonprofit hospital probe

Patients, digital health players weigh in on FTC's data privacy plan

Alabama IVF ruling threatens families facing fatal genetic disease

The Harvard botanist who searched for psychedelics in the Amazon

knowledge

focus

explore

In Memoriam: Notable people who died in 2023

Illumina slashes 2023 revenue projections yet again

DIEP, the 'gold standard' of breast reconstruction, is under threat

Hospitals are dialing back on venture capital investing

FDA approval of Sarepta Duchenne genetic therapy gives me hope

BMS, looking to build heart drug business, turns to AI for diagnosis

Hepatitis C has a cure — but many Americans still lack access to it

What to know about the judge who will handle the Trump case

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Alabama IVF ruling threatens families facing fatal genetic disease

Wikipedia

In utero gene editing: an explainer

Hospitals are dialing back on venture capital investing

YouTube cracks down on misinformation on cancer treatment

Health AI: on the border between health care and tech

Timeline: How the deadly wildfires took over Maui day by day

Dozens dead from Maui wildfires: What we know about the victims

leisure time

focus

focus

explore